223 related articles for article (PubMed ID: 19093004)
21. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
[TBL] [Abstract][Full Text] [Related]
22. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
23. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
Ellis RD; Wu Y; Martin LB; Shaffer D; Miura K; Aebig J; Orcutt A; Rausch K; Zhu D; Mogensen A; Fay MP; Narum DL; Long C; Miller L; Durbin AP
PLoS One; 2012; 7(10):e46094. PubMed ID: 23056238
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.
Gregson AL; Oliveira G; Othoro C; Calvo-Calle JM; Thorton GB; Nardin E; Edelman R
PLoS One; 2008 Feb; 3(2):e1556. PubMed ID: 18253503
[TBL] [Abstract][Full Text] [Related]
27. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.
McCarthy JS; Marjason J; Elliott S; Fahey P; Bang G; Malkin E; Tierney E; Aked-Hurditch H; Adda C; Cross N; Richards JS; Fowkes FJ; Boyle MJ; Long C; Druilhe P; Beeson JG; Anders RF
PLoS One; 2011; 6(9):e24413. PubMed ID: 21949716
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
Hu J; Chen Z; Gu J; Wan M; Shen Q; Kieny MP; He J; Li Z; Zhang Q; Reed ZH; Zhu Y; Li W; Cao Y; Qu L; Cao Z; Wang Q; Liu H; Pan X; Huang X; Zhang D; Xue X; Pan W
PLoS One; 2008 Apr; 3(4):e1952. PubMed ID: 18398475
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
32. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.
Audran R; Lurati-Ruiz F; Genton B; Blythman HE; Ofori-Anyinam O; Reymond C; Corradin G; Spertini F
PLoS One; 2009 Oct; 4(10):e7304. PubMed ID: 19798415
[TBL] [Abstract][Full Text] [Related]
33. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
35. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
[TBL] [Abstract][Full Text] [Related]
36. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.
Druilhe P; Spertini F; Soesoe D; Corradin G; Mejia P; Singh S; Audran R; Bouzidi A; Oeuvray C; Roussilhon C
PLoS Med; 2005 Nov; 2(11):e344. PubMed ID: 16262450
[TBL] [Abstract][Full Text] [Related]
37. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
Sagara I; Ellis RD; Dicko A; Niambele MB; Kamate B; Guindo O; Sissoko MS; Fay MP; Guindo MA; Kante O; Saye R; Miura K; Long C; Mullen GE; Pierce M; Martin LB; Rausch K; Dolo A; Diallo DA; Miller LH; Doumbo OK
Vaccine; 2009 Dec; 27(52):7292-8. PubMed ID: 19874925
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques.
Langermans JA; Hensmann M; van Gijlswiik M; Zhang D; Pan W; Giersing BK; Locke E; Dubovsk F; Wittes J; Thomas AW
Hum Vaccin; 2006; 2(5):222-6. PubMed ID: 17035731
[TBL] [Abstract][Full Text] [Related]
39. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.
Arévalo-Herrera M; Vera O; Castellanos A; Céspedes N; Soto L; Corradin G; Herrera S
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):21-7. PubMed ID: 21292874
[TBL] [Abstract][Full Text] [Related]
40. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
Ellis RD; Mullen GE; Pierce M; Martin LB; Miura K; Fay MP; Long CA; Shaffer D; Saul A; Miller LH; Durbin AP
Vaccine; 2009 Jun; 27(31):4104-9. PubMed ID: 19410624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
